 SEATTLE, Aug. 05, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that Steven Quay, M.D., Ph.D., Atossas President and CEO, and Kyle Guse, Atossas Chief Financial Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9-10, 2021. 